IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Bought by Balyasny Asset Management L.P.

Balyasny Asset Management L.P. boosted its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 230.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,455 shares of the company's stock after buying an additional 1,712 shares during the quarter. Balyasny Asset Management L.P.'s holdings in IDEXX Laboratories were worth $1,015,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of IDXX. United Capital Financial Advisors LLC raised its stake in IDEXX Laboratories by 0.9% during the fourth quarter. United Capital Financial Advisors LLC now owns 2,446 shares of the company's stock valued at $1,011,000 after purchasing an additional 22 shares in the last quarter. Cranbrook Wealth Management LLC raised its stake in IDEXX Laboratories by 7.0% during the fourth quarter. Cranbrook Wealth Management LLC now owns 382 shares of the company's stock valued at $158,000 after purchasing an additional 25 shares in the last quarter. Gabelli Funds LLC raised its stake in IDEXX Laboratories by 5.3% during the fourth quarter. Gabelli Funds LLC now owns 500 shares of the company's stock valued at $207,000 after purchasing an additional 25 shares in the last quarter. Perigon Wealth Management LLC raised its stake in IDEXX Laboratories by 1.8% during the fourth quarter. Perigon Wealth Management LLC now owns 1,474 shares of the company's stock valued at $632,000 after purchasing an additional 26 shares in the last quarter. Finally, Summit Trail Advisors LLC raised its stake in IDEXX Laboratories by 3.3% during the fourth quarter. Summit Trail Advisors LLC now owns 810 shares of the company's stock valued at $335,000 after purchasing an additional 26 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

IDXX has been the topic of a number of recent research reports. Stifel Nicolaus upped their price target on shares of IDEXX Laboratories from $460.00 to $510.00 and gave the company a "hold" rating in a research note on Monday. Bank of America increased their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research note on Tuesday, February 4th. Morgan Stanley increased their target price on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the company an "overweight" rating in a research note on Monday, May 5th. StockNews.com upgraded shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a report on Friday, May 9th. Finally, Barclays increased their target price on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a report on Tuesday, February 4th. Three research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $536.00.

IDEXX Laboratories Stock Performance

Shares of NASDAQ IDXX traded up $1.70 during midday trading on Tuesday, reaching $523.38. 85,598 shares of the stock were exchanged, compared to its average volume of 806,262. The firm has a market cap of $42.09 billion, a price-to-earnings ratio of 49.05, a PEG ratio of 3.41 and a beta of 1.52. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $530.60. The firm has a 50-day simple moving average of $433.47 and a two-hundred day simple moving average of $432.18. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported $2.96 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.93 by $0.03. IDEXX Laboratories had a net margin of 22.78% and a return on equity of 55.82%. The firm had revenue of $998.43 million for the quarter, compared to analysts' expectations of $998.25 million. During the same quarter last year, the company earned $2.71 EPS. The firm's revenue for the quarter was up 3.6% compared to the same quarter last year. As a group, analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.